Fol. Biol. 2026, 72, 85-94
https://doi.org/10.14712/fb2026.0009
MiR-26b-5p Predicts the Severity of Crohn’s Disease and the Degree of Malnutrition
Yan-Hui Sun1
, Xiao-Xiao Wang2, Cong Wu1
, Xiao-Xiao Wang2, Cong Wu1
1Department of Nutrition, the Seventh Medical Center of Chinese PLA General Hospital, Beijing, 100700, China
2Department of Obstetrics and Gynecology, the Seventh Medical Center of Chinese PLA General Hospital, Beijing, 100700, China
Received September 24, 2025
Accepted January 16, 2026
References
1. , G., Lungaro, L., Caputo, F. et al. (2021) Nutritional treatment in Crohn’s disease. Nutrients 13, 1628.
<https://doi.org/10.3390/nu13051628>
2. , E., Wiest, R., Scharl, M. et al. (2021) Dysbiotic microbiota interactions in Crohn’s disease. Gut Microbes 13, 1949096.
<https://doi.org/10.1080/19490976.2021.1949096>
3. , H., Hughes, D., Kirkham, J.J. et al. (2019) Systematic review: outcomes and adverse events from randomised trials in Crohn’s disease. Aliment. Pharmacol. Ther. 49, 978-996.
<https://doi.org/10.1111/apt.15174>
4. , J. N., Omer, O. S., Tasker, S. et al. (2020) Regulatory T-cell therapy in Crohn’s disease: challenges and advances. Gut 69, 942-952.
<https://doi.org/10.1136/gutjnl-2019-319850>
5. , M., Torres, J., Vermeire, S. (2024) Crohn’s disease. Lancet 403, 1177-1191.
<https://doi.org/10.1016/S0140-6736(23)02586-2>
6. , J., Zhao, X., Hu, S. et al. (2022) Gut microbial DL-endopeptidase alleviates Crohn’s disease via the NOD2 pathway. Cell Host Microbe 30, 1435-1449.e9.
<https://doi.org/10.1016/j.chom.2022.08.002>
7. , Chinese Society of Gastroenterology, Chinese Medical Association (2021) Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing). J. Dig. Dis. 22, 298-317.
<https://doi.org/10.1111/1751-2980.12994>
8. , B., Mrowiec, S. (2023) Nutritional status and its detection in patients with inflammatory bowel diseases. Nutrients 15, 1991.
<https://doi.org/10.3390/nu15081991>
9. , M., Kothari, S., Gohir, W. et al. (2023) MicroRNAs in infectious diseases: potential diagnostic biomarkers and therapeutic targets. Clin. Microbiol. Rev. 36, e0001523.
<https://doi.org/10.1128/cmr.00015-23>
10. , J., Rasmussen, H. H., Hamberg, O. et al. (2003) Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin. Nutr. 22, 321-336.
<https://doi.org/10.1016/S0261-5614(02)00214-5>
11. , E., Katsanos, K. H. (2016) Implementation of the simple endoscopic activity score in Crohn’s disease. Saudi J. Gastroenterol. 22, 183-191.
<https://doi.org/10.4103/1319-3767.182455>
12. , S. J., Lewis, A., Nijhuis, A., Jeffery, R. et al. (2018) Epithelial down-regulation of the miR-200 family in fibrostenosing Crohn’s disease is associated with features of epithelial to mesenchymal transition. J. Cell. Mol. Med. 22, 5617-5628.
<https://doi.org/10.1111/jcmm.13836>
13. , A., Abd-Aziz, N., Khalid, K. et al. (2022) miRNA: a promising therapeutic target in cancer. Int. J. Mol. Sci. 23, 11502.
<https://doi.org/10.3390/ijms231911502>
14. , P., Zhang, L., Li, S. et al. (2024) The emerging role of oxidative stress in inflammatory bowel disease. Front. Endocrinol. (Lausanne) 15, 1390351.
<https://doi.org/10.3389/fendo.2024.1390351>
15. Hoen, E. N., Van Rooij, E., Bushell, M. et al. (2015) The role of microRNA in nutritional control. J. Intern. Med. 278, 99-109.
<https://doi.org/10.1111/joim.12372>
16. , D., Cosín-Roger, J., Calatayud, S. et al. (2016) M1 macrophages activate Notch signalling in epithelial cells: relevance in Crohn’s disease. J. Crohns Colitis 10, 582-592.
<https://doi.org/10.1093/ecco-jcc/jjw009>
17. , G., Chrzanowski, G., Aebisher, D. et al. (2023) Crohn’s disease: basic characteristics of the disease, diagnostic methods, the role of biomarkers, and analysis of metalloproteinases: a review. Life (Basel) 13, 2062.
18. , L., Gori, R., Elli, L. et al. (2022) Nutrition in patients with inflammatory bowel diseases: a narrative review. Nutrients 14, 751.
<https://doi.org/10.3390/nu14040751>
19. , K., Le, N., von Arnim, U. et al. (2018) Circulating and fecal microRNAs as biomarkers for inflammatory bowel diseases. Inflamm. Bowel Dis. 24, 1547-1557.
<https://doi.org/10.1093/ibd/izy046>
20. , C. D. (2024) MicroRNAs and cardiovascular disease risk. Curr. Cardiol. Rep. 26, 51-60.
<https://doi.org/10.1007/s11886-023-02014-1>
21. , M. S., Satsangi, J., Ahmad, T. et al. (2005) Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can. J. Gastroenterol. 19 (Suppl. A), 5A-36A.
<https://doi.org/10.1155/2005/269076>
22. , J., Mehandru, S., Colombel, J. F. et al. (2017) Crohn’s disease. Lancet 389, 1741-1755.
<https://doi.org/10.1016/S0140-6736(16)31711-1>
23. , R., Bernstein, C. N., Gearry, R. et al. (2014) Antibiotics associated with increased risk of new-onset Crohn’s disease but not ulcerative colitis: a meta-analysis. Am. J. Gastroenterol. 109, 1728-1738.
<https://doi.org/10.1038/ajg.2014.246>
24. , K. L., Zheng, L. B., Kanazawa, Y. et al. (2014) Immunopathology of inflammatory bowel disease. World J. Gastroenterol. 20, 6-21.
<https://doi.org/10.3748/wjg.v20.i1.6>
25. , Z., Zhou, H., Cheng, F. et al. (2022) MiR-21 regulates epithelial-mesenchymal transition in intestinal fibrosis of Crohn’s disease by targeting PTEN/mTOR. Dig. Liver Dis. 54, 1358-1366.
<https://doi.org/10.1016/j.dld.2022.04.007>
26. , C.P., Bi, Y. J., Liu, D. M. et al. (2019) Hsa-miR-375 promotes the progression of inflammatory bowel disease by upregulating TLR4. Eur. Rev. Med. Pharmacol. Sci. 23, 7543-7549.
27. , F., Carlson, S. A., Liu, Y. et al. (2021) Prevalence of inflammatory bowel disease among medicare fee-for-service beneficiaries - United States, 2001-2018. MMWR Morb. Mortal. Wkly Rep. 70, 698-701.
<https://doi.org/10.15585/mmwr.mm7019a2>
28. , J., Guo, Z., Wang, Z. et al. (2023) Fecal miR-223 is a noninvasive biomarker for estimating Crohn’s disease activity. Immun. Inflamm. Dis. 11, e1131.
<https://doi.org/10.1002/iid3.1131>
29. , Q., Liu, Y., Li, Y. et al. (2025) Implications of gut microbiota-mediated epigenetic modifications in intestinal diseases. Gut Microbes 17, 2508426.
<https://doi.org/10.1080/19490976.2025.2508426>
